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ABSTRACT 
 
Metoclopramide hydrochloride (MCP) is commonly used for the management ofgastrointestinal 
disorders. Frequent administration and the undesired side effects (extrapyramidal  symptoms) of 
the drug on the central nervous system due to the fluctuationsof its plasma concentrations may 
lead to patient incompliance, and hence, impropertherapy. Therefore, the present work will be 
devoted to formulate the drug in sustainedrelease formulations. Metoclopramide hydrochloride 
MCP was incorporated in 7 formulae containing differentpolymers and/or different polymer 
ratios. These polymers were hydroxypropylmethylcellulose (HPMC), Sodium 
carboxymethylcellulose (CMC).Mannitolwas added to f4-f7 formulae in different amounts in 
order tosoften and/or disintegrate the tablets. Both direct compression and 
granulationtechniques were used to prepare the tablets. The physical properties were found to 
besatisfactory for all the formulae. The dissolution profiles of the tablets were constructedusing 
the change-over method. The drug release involved a combination of bothdiffusion and 
polymer-chain relaxation mechanisms. The time required to release 50%of MCP ranged from 
1.2 to more than 8 hours. Direct compression technique produced sufficient sustaining of the 
drug release.  
 
Keywords: Metoclopromide HCL,sustained release. HPMC, SCMC. 
  
INTRODUCTION 
 
Oral drug delivery has been known for decades as the most widely utilized route of administered 
among all the routes that have been employed for the systemic delivery of drug via various 
pharmaceutical products of different dosage forms. The reasons that the oral route achieved such 
popularity may be in part attributed to its ease of administration and the belief that oral 
administration of the drug is well absorbed1. 
All the pharmaceutical products formulated for systemic delivery via the oral route of 
administration irrespective of the mode of delivery (immediate sustained or controlled release) 
and the design of dosage forms (either solid dispersion or liquid) , must be developed within the 
intrinsic characteristics of GI physiology , pharmacokinetics , pharmacodynamics and 
formulation design is essential to achieve a systemic approach to the successful development of 
an oral pharmaceutical dosage form.2,3 
 
RATIONAL OF SUSTAINED AND CONTROLLED DRUG DELIVERY 
 
The basic rational for controlled drug delivery is to alter the pharmacokinetic and 
pharmacodynamics of pharmacological active moieties by using novel drug delivery system or 
by modifying the molecular structure and physiological parameters inherent in the selected route 
of administration. It is desirable that the duration of drug action becomes more a design property 
of a rate controlled dosage form and less or not at all a property of the drug molecules properties, 
inherent kinetics. Thus optional design of controlled release systems necessitates a thorough 
understanding of the pharmacokinetics and pharmacodynamics of the drugs. 
 
 
 
 
SUSTAINED AND CONTROLLED RELEASE DRUG DELIVERY SYSTEMS 
 
Over the Past 30 years, as the expense and complications involved on marketing new drug 
entities have increased , with concomitant recognition of the therapeutic advantages of controlled 
drug delivery , greater attention has been focused on development of sustained or controlled 
release drug delivery systems. The attractiveness of these dosage forms is due to awareness to 
toxicity and infectiveness of drugs when administered or applied by conventional method in the 
form off tablets, capsules , injectables , ointments etc. Usually conventional dosage form 
produces wide- ranging fluctuation in drug concentration in the bloodstream and tissues with 
consequent undesirable toxicity and poor efficiency. These factors as well as factors such as 
repetitive dosing and unpredictable absorption lead to the concept of controlled delivery systems. 
The goal in designing sustained or controlled delivery system is to reduce the frequency of the 
dosing or to increase effectiveness of the drug by localization at the site of action, reducing the 
dose required or providing uniform drug delivery. So sustained release dosage form is a dosage 
form that release one or more drugs continuously in predetermined pattern for a fixed period of 
time, either systematically or to a specified target organ. Sustained release dosage forms provide 
a better control of plasma drug level, less dosage forms provide a better control of plasma drug 
levels, less dosage frequency, less side effect, increased efficiency and constant delivery. 
 
2.1 Terminology4 
Modified release delivery system may be divided conveniently into four categories. 
1. delayed release 
2. sustained release 
• controlled release 
• extended release 
 
 
 
Delayed release: 
These systems are those that use repetitive, intermittent dosing of a drug from one or more 
immediate release units incorporated into a single dosage form. Examples of delayed release 
systems include repeated action tablets and capsules and enteric-coated tablets where timed to 
release is achieve by a barrier coating. 
Sustained release: 
These systems include any drug delivery system that achieves slow, release of drug over an 
extended period of time. 
 
Controlled release: 
These system also provide a slow release of drug over an extended period of a time and can 
provide some control, whether this be of a temporal or spatial nature, or both, of drug release in 
the body, or in other words, the system is successful at maintaining constant drug levels in the 
target tissue or cells. 
 
Extended Release: 
Pharmaceutical dosage forms that release the drug slower than normal manner of predetermined 
rate & necessarily reduce the dosage frequency by two folds. 
 
Site specific targeting drug delivery: 
These systems refer to targeting of a drug directly to a certain biological location. In this case the 
target is adjacent to or in the diseased organ or tissue. 
 
 
 
Receptor targeting Drug Delivery: 
These systems refer to targeting of a drug directly to a certain biological location. In this case the 
target is the particular receptor for a drug within an organ or tissue. 
Site specific targeting & receptor targeting systems satisfy the spatial aspect of drug delivery & 
are also considered to be controlled drug delivery system. 
 
2.2 Release Rate and Dose Consideration: 
As already mention, conventional dosage forms include solutions, Capsules, tablets, emulsions, 
aerosols, foams, ointment & suppositories. These dosage forms can be release their active 
ingredients into an absorption pool immediately. 
 
Kr                                          KaKe 
Dosage form -----Æ  Absorption pool ----Æ Target area----ÆElimination 
Drug Release                          absorption 
 
Kr = First order rate constant for drug release. 
Ka = First order rate constant for drug absorption. 
Ke   = First order rate constant for overall drug elimination. 
 
For immediate release dosage forms Kr   >>>  Ka  or alternatively absorption of drug across a 
biological membrane is the rate- limiting step in delivery of the drug to its target area. 
For non-immediate release dosage forms , Kr <<< Ka , that is, release of drug from the dosage 
form is the rate  limiting step. This cause the above kinetics scheme to reduce to . 
 Kr                                                     Ke 
Dosage form -----------------Æ  Target Area --------------Æelimination 
Drug Release 
 
Thus, the effort to develop a no immediate release delivery system must be directed primarily by 
altering the release rate by affecting the value of Kr. 
The ideal goal of designing sustained –release system is to deliver drug to the desired site at a 
rate according to needs of the body,i.e., a self regulated system based on its feedback control the 
release system but this is a difficult assignment. 
The pivotal question is at what rate should be drug delivered to maintain a constant blood drug 
level? This constant rate should be analogous to that achieved by continuous intravenous 
infusion where a drug is provided to the patient at a constant rate s just equal to its rate of 
elimination. This implies that the rate of delivery must be independent on the amount of drug 
remaining in the dosage form & constant over time. That is , release from the dosage form 
should follow Zero-order kinetics, as shown by, 
 
Kro = Rate in=Rate out= Ke Cd Vd 
Where 
Kro=  Zero order rate constant for drug release(amount/time) 
Ke = First order rate constant for overall drug elimination(time”) 
Cd= Desired drug level in the body(amount/volume) 
Vd = Volume space in which the drug is distributed. 
 
For many drug, more complex elimination kinetics and other factors affects their deposition. 
This is then affects the nature of release kinetics necessory to maintain a constant drug level. It is 
important to recognize that while Zero -  order release may be desirable theoretically; non Zero-
order release may be equivalent clinically to constant release in many cases. Aside from the 
extent of intra and inter subject variation is the observation that for many drugs, modest changes 
in drug tissue levels do not result in an improvement in clinical performance. Thus, a constant 
drug level may be indistinguishable clinically from a constant drug level. 
To achieve a therapeutic level promptly and sustain the level for a given period of time, the 
dosage generally consists of two parts: an initial primary dose, Di, that releases drug immediately 
and a maintenance or sustaining dose, Dm. 
 
The total dose, W, thus required for the system is 
W= Di |+ Dm 
For a system in which the maintenance dose releases the drug by a zero order process for a 
specified period of time, the total dose is 
 
W= Di + Kr0 Td 
 
Kr0= Zero order rate constant for drug release 
Td =  Total time desired for a sustained release from one dose. 
 
If the maintenance dose begins to release  the drug at the time of dosing (t=0), it will add to that 
which is provided by the initial dose, thus increasing the initial drug level. In this case a 
correction factor is needed to account for the added drug from the maintenance dose. 
 
W=Di + Kr0 Td – Kr 0 Kr 0Tp 
 
The correction factor  , Kr 0Tp is the amount of drug provided  during the period from t=0 to the 
time of the peak drug level , Tp  No correction factor is needed if the dosage form is constructed 
in such a fashion that the maintenance dose not begin to release drug until time Tp. 
Suitable combination of the initial dose and maintenance dose that releases its drug can be 
obtained satisfactorily in approximation of a constant drug level by a first order process. 
 
The total dose for such a system is 
W=Di +(KeCd/Kr)Vd 
 
Kr =   first order drug release constant (time 1) 
If the maintenance dose begins releasing drug at t = 0, a correction factor is required just as it 
was in the zero order case. The correction expression in this case  
 
W= Di +(KeCd/Kr)Vd-DmKeTp 
 
To maintain drug blood levels within the therapeutic range over the entire time course of therapy, 
most sustained release drug delivery systems are ,like conventional dosage forms,administred as 
multiple rather than single doses. For an idel sustained– release system that releases drug by 
zero- order kinetics, the multiple dosing regimens is analogous to that used for a constant 
intravenous infusion. For those sustain-release systems having release kinetics other than zero-
order, the multiple dosing regimens are more complex. 
 
2.3Oral Sustained and controlled Release System: 
• Total 5 types of oral controlled release systems are available. 
• Dissolution controlled release system. 
• Diffusion controlled system. 
• Bioerodible and combination diffusion and dissolution system. 
• Osmotically controlled release system. 
• Ion exchange systems. 
2.3.1 Dissolution controlled release system: 6 
A drug with a slow dissolution rate will sustain release rate of the drug from the dosage form. 
Here the rate –limiting step is dissolution.This is true, sustain release preparation of drugs could 
be made by decreasing their rate of dissolution. These approaches are achieved by preparing 
appropriate salts or derivatives, coating the drug with a slow dissolving material or incorporating 
it into a tablet with a slowly dissolving carrier. 
 
 
Figure .1. Schematic representation of dissolution controlled release system 
      (a) matrix system , 
(b) coated / encapsulated system 
Soluble drug
Slowly dissolving or 
erodible matrix
Slowly dissolving  
 Dissolution controlled systems can be made either by rate controlling coats or by administering 
the drugs as a group of beads that have coating of different thickness. In first case if the outer 
layer is a quickly releasing bouls of drug, initial levels of drug in the body can be quickly 
established with plused intervals. 
In second case since the beads have different coating thickness; there release will occur in 
progressive manner. Those with the thinnest layer will provide the initial dose and the 
maintenance of drug levels at later times will be achieved from those with thicker coating. The 
Noyes – Whitney equation, describes this dissolution process at steady state 
 
Dc                               D 
---- = KD A (Cs-C) = ----    A (Cs-C) 
Dt                              h 
 
Where, 
Dc/dt    = dissolution rate 
Kr         = dissolution rate constant. 
D         =   diffusion coefficient 
Cs        =   Saturation solubility of the solid. 
C         =    Concentration of solute in the bulk solution. 
The above equation predicts that the rate release can be constant only if the following parameters 
are constant. 
a) Surface area 
b) Diffusion coefficient 
c) Diffusion layer thickness 
 i. Concentration difference. 
But these parameters are not easily maintained constant, especially surface area. For spherical 
particles, the change in surface area can be related to the weight of the particle that is under 
assumption of sink conditions, above equation can be rewritten as cube root dissolution equation. 
 
W0 1/3  -  W  1/3   = KDt 
 
Where, 
Kd      = cube root dissolution rate constant 
Wo     = Initial weight 
W       = weight of the amount remaining at time t 
2.3.2 Diffusion systems: 
 
In this system release rate of a drug being dependent on its diffusion through an inert membrane 
barrier. Usually, this barrier is an insoluble polymer , it’s again having two  subclasses. 
a) Reservoir devices 
b) Matrix devices. 
 
a) Reservoir devices: 
Reservoir devices are characterized by a core of drug, the reservoir, surrounded by a polymeric 
membrane and also the nature of the membrane determines the rate of release of drug from the 
system. 
  
 
Figure 2.Drug release of diffusion across the insoluble membrane of 
Reservoir device 
 
The process of diffusion is described by Ficks equation. This equation states that the amount of 
drug passing across a unit area is proportional to the concentration differences across that barrier. 
The equation is given as 
J= Ddc/dx……………………(1) 
 
Where ‘J’ given in units of amount/area-time, ‘D’ is the diffusion coefficient of the drug in the 
membrane (Area/time), dc/dx represents the rate of change in concentration ‘C’ relative to a 
distance ‘X’ in the membrane. 
Equation (1)  can be integrated and simplified to give. 
 
Insoluble membrane 
Reservoir of drug (alone or 
as matrix with inert diluents) 
Diffusion of soluble drug 
by partitioning
J=DK        C/d …………… (2) 
Where 
K      = Partition co-efficient 
c    = Concentration difference across the membrane. 
d       = Thickness of the diffusion layer. 
In the equation (2)   it is assumed that “D” and ‘k’ are constant. 
Drug release will vary, depending on the geometry of the system 6 ..The Simplest system to 
consider is that of a slab, where drug release is from only one surface. In this case equation (2) 
can be written as 
 
dMt=   ADK   C   --------------(3) 
dt                 d 
 
Where 
‘Mt’ is the mass of drug released after time‘t’ 
d Mt /dt the steady – state release rate at time ‘t’ and 
‘A’ the surface area of the device. 
 
The left side of equation (3) represents the release rate of the system. A true controlled release 
system with a zero –order rate can be possible if all the variables on the right side of equation (3) 
remain constant. But it is very difficult to maintain all the parameters constants. Again depending 
on the device diffusion systems can provide constant release at steady state. For reservoir 
devices, a system that is used relatively soon after construction will demonstrate a large time in 
release, since it will take time for 
 
the drug to diffuse from the reservoir to the membrane surface. On the other hand, systems that 
are stored will demonstrate a burst effect, since, on standing the membrane becomes saturated 
with available drug. The magnitude of these effects is dependent on the diffusing distance (i.e. 
the membrane thickness). 
 
Advantages: 
i) This device can offer zero-order release of the drug. 
ii) Kinetics of a particular drug can be controlled by changing the characteristics of the 
polymer to meet the particular therapeutic conditions. 
Disadvantages: 
i) System must be physically removed from implant sites. 
ii) Difficult to deliver high molecular weight compounds. 
iii) Generally increased cost per dosage unit. 
iv) Potential toxicity if system fails. 
 
a) Matrix devices: 
Matrix devices consist of drug dispersed homogeneously throughout a polymer matrix, in the 
model, drug in the outside layer exposed to the bathing solution when it is dissolved first and 
then diffuses out of the matrix. This process continues with the interface between the bathing 
solution and the solid drug moving toward the interior. For this system rate of dissolution of drug 
particles within the matrix must be much faster than the diffusion rate of the dissolved drug 
leaving the matrix.` 
 Figure.3. Diffusion controlled devices---(a)rigid matrix , and (b) swellable matrix. 
The rate of release of drugs dispersed in an inert matrix system , have been derived by Higuchi. 
 
dM / dh =Codh-Cs/2. –(1) 
Where, 
dM = Change in the amount of drug released per unit area. 
dh   = change in the thickness of the zone of matrix that has been depleted of 
drug. 
Co   = total amount of drug in a unit volume of the matrix. 
Cs   =   saturated concentration of the drug within the matrix. 
From diffusion theory, 
dM = (DmCs/h). dt         --------------------(2) 
Insoluble rigid 
matrix
  Drug 
Swollen glassy hydrogel 
from which drug has 
completely diffused
Sellable 
gum
Where, 
Dm is the diffusion coefficient in the matrix 
equation (1) and (2) integrating and solving for  ‘h’ gives. 
M =[(CsDm2C0-Cs) t]1/2   ------------------------(3) 
When amount of drug is in excess of the saturation concentration that is Co>> Cs 
M =  [2CsDmCot]  1/2        ---------------------(4) 
Equation (4) indicates that the amount of drug released is a function of the square root of time. 
The drug release from a porous or granular matrix can be described by 
M= (Ds. Ca {P/T} [2Co –Pca]t)1/2 
 
Where 
P = porosity of the matrix. 
T = tortuosity 
Ca = solubility of the drug in the release medium 
D5 = diffusion coefficient in the release medium. 
 
The system is slightly different from the previous matrix system in that the drug is able to pass 
out of the matrix through fluid filled channels and does not pass through the polymer directly 
 
Advantages of matrix diffusion system: 
i) Easier to produce that reservoir devices. 
ii) Can deliver high molecular weight compounds 
Disadvantages of matrix diffusion system: 
i) Cannot obtain zero order release. 
ii) Removal of remaining matrix is necessary for implanted system. 
 
2.3.3. Bioerodible and combination diffusion and dissolution systems7,8,9 
 
Therapeutic systems are not only dependent on either dissolution or diffusion system. In practice, 
the dominant mechanism for release will be either  dissolution rate limited or diffusion controlled 
Bioerodible devices constitute a group of system for which release characteristics are complex. 
The mechanism of release from simple erodible slabs, cylinders and spheres can be described by 
following mathematical model. 
Mt /M  =    1-(1-Kot/Coa)n 
Where, 
Mt    = Mass of drug release at time t 
M    =    Mass release at infinite time 
a     =    Radius of sphere or cylinder or the half height of a slab. 
n     =    3 for a sphere, 2 for a cylinder and 1 for a slab. 
 
This system is the combination of both diffusion and dissolution of matrix material and the drug. 
Drug not only can diffuse out of the dosage form but the matrix itself undergoes a dissolution 
process. 
The complexity of the system arises from the fact that as the polymer dissolves; the diffusion 
path length of the drug may change. This usually results in a moving boundary diffusion system. 
Zero order release can occur only if surface erosion occurs and surface area does not change with 
time. 
An advantage of such a system is that the bioerodible property of the matrix does not result in a 
host matrix. The disadvantage of these matrix systems is that release kinetics is often hard to 
control. 
Another method for the preparation of bioerodible system is to attach the drug directly to the 
polymer by a chemical bond. Generally drug is released from the polymer by hydrolysis or 
enzymatic reactions. 
Advantage of such system is control of the rate of release somewhat easier. Another advantage of 
the system is the ability to achieve very high drug loading. 
Third type is the swelling controlled matrix. Here the drug is dissolved in the polymer, but 
instead of an insoluble or eroding polymer. Swelling of the polymer occurs. This allows entrance 
of water, which causes dissolution of the drug and diffusion out of the swollen matrix. In these 
systems the release rate is highly dependent on the polymer swelling rate, drug solubility and the 
amount of soluble fraction in the matrix. This system usually minimizes burst effects, since 
polymer swelling must occur before drug release. 
2.3.4. Osmotically controlled system: 
In these systems, osmotic pressure provides the driving force to generate controlled release of 
drug. In this system a tablet containing a core of drug surrounded by a semipermiable membrane, 
which is permeable to water, but not to drug. When this device is exposed to water or any body 
fluid, water will flow into the tablet owing to the osmotic pressure difference. The rate of flow , 
dv/dt, of water into the device can be represented by as. 
 
Dv/dt = AK/h   (     T   -    P) 
Where, 
K        = Membrane permeability 
A        = Area of the Membrane 
H       = Membrane thickness 
T      = Osmotic pressure difference 
P      =   Hydrostatic pressure difference. 
These systems are generally appear in two different forms: 
• The drug as a solid core together with electrolyte, which is dissolved by the incoming 
water. The electrolyte provides the high osmotic pressure difference. 
• This system contains the drug in solution in an impermeable membrane within device. 
The electrolyte surrounds the bag. 
Advantages: 
i. This system can deliver large volumes and some are refillable. 
ii. Release of drug is in theory independent of the drug’s properties. 
iii. Zero order release is obtainable. 
Disadvantages: 
i. Systems can be much more expensive than conventional counterparts. 
ii. Quality control is more expensive than most conventional tablets. 
 
2.3.5. Ion exchange systems: 
This system generally uses resins composed of water insoluble cross linked polymers. These 
polymers contain salt forming functional groups in repeating positions on the polymer chain. The 
drug is bound to the resin and released by exchanging with appropriately changed ions in 
contacting with the ion exchange groups. 
Resin  +- drug-+x ---------Æ Resin+- X-- + drug – 
Resin  +- drug-+Y ---------Æ Resin+- Y-- + drug + 
 
Where X- and Y+ are ions in the GI tract. The free drug then diffuses out of the resin. The drug 
resin complex is prepared either by repeated exposure of the resin to the drug in a 
chromatography column, or by prolonged contact in solution. 
The rate of drug diffusing out of the resin is controlled by the area of diffusion, diffusion path 
length and rigidity of the resin, which is a function of the amount of cross-linking agent used to 
prepare the resin. 
The system is advantageous for drugs that are highly susceptible to degradation by enzymatic 
process, since it offers a protective mechanism by temporarily altering the substrate. The 
limitation of this system is to release rate which is proportional to the concentration of the ions 
present in the area of administration. 
2.4Drug properties relevant to controlled release formulation : 
The design of controlled –release delivery system is subject to several variables of considerable 
importance. Among these are the route of drug delivery, the type of delivery system, the disease 
being treated, the patient, the length of therapy and the properties of the drug. Each of these 
variables are interrelated and this imposes certain constrains upon choices for the route of 
delivery, the design of the delivery system and the length of therapy. Properties of drugs are very 
important for designing a sustained release dosage form mainly physicochemical and biological 
properties of the drug are most important. 
2.5Metoclopramide and ExtrapyramidalSymptoms: 
Metoclopramide is a usefulmedication in the anesthesia provider’sarmamentarium. Its primary 
indication in the preoperativephase is to reduce gastric contents and increase lower 
esophagealsphincter tone for pharmacologic pulmonary aspiration prophylaxis. Metoclopramide 
can precipitate extrapyramidal symptoms(EPS)/drug-inducedmovement disorders (DIMD). 
Tardive dyskinesia and Parkinsonism generally seen after long-termuse,whereasdystonia and 
akathisia can occur after a single dose of metoclo-pramide. Recognition of dystonia and/or 
akathisia by the peri-anesthesia nurse after the administration of metoclopramide isimportant for 
prompt treatment of this distressing condition. It isimperative that the perianesthesia nurse is 
knowledgeable in metoclopramide’s basic pharmacology, uses as an anesthetic 
adjunct,guidelines for administration, and EPS/DIMD associated reactions,as well 
asmeasuresthatmay reduce the incidence and/or facilitatetreatment of this medication-induced 
condition. This case reportpresents a male patient in his 40s experiencing akathisia after asingle 
10-mg dose of metoclopramide.Keywords: metoclopramide, extrapyramidal symptoms, drug 
induced movement disorders, akathisia, case study, perianesthesiacare. 
METOCLOPRAMIDE is a useful medicationin the anesthesia provider’s armamentarium.It is 
administered in the preoperative phaseto reduce gastric contents and increase loweresophageal 
sphincter tone for pharmacologicpulmonary aspiration prophylaxis. Metoclopramide can result in 
extrapyramidal symptoms (EPS)/drug-induced movement disorder(DIMD) when administered 
during the perianesthesia/perioperative period. 
  
LITERATURE REVEIW 
ShalinModiet al(2011)10:Now a days as very few drugs are coming out of research and 
development and already existing drugs are suffering the problem of resistance due to their 
irrational use specifically in case of drugs like antibiotics. Hence, change in the operation is a 
suitable and optimized way to make the some drug more effective by slight alteration in the drug 
delivery.Sustained Release is also providing promising way to decrease the side effect of drug by 
preventing the fluctuation of the therapeutic concentration of the drug in the body. This article 
contains the basic information regarding sustained-release formulationand also the different 
types of the same. 
Ramdaset al (2011)11: Oral sustained release dosage forms are the most commonly formulated 
but still offer highest attention in the area of novel drug delivery systems. (1-2). This system can 
also help in optimizing oral controlled delivery of drugs having ‘absorption window’ by 
continuously releasing drug prior to absorption window, for prolonged period of time thus 
causing optimal bioavailability (3). Gastric emptying of dosage forms is an extremely variable 
process and ability to prolong and control the emptying time is a valuable asset for dosage forms, 
which reside in the stomach for a longer period of time than conventional dosage forms (4). 
Prolonged gastric residence time (GRT) and controlled release of drugs within the GI tract helps 
to reduce dosing frequency and total dose, improve patient compliance and convenience, 
maintain a less fluctuating plasma level, as well as reduce GI side effects. Prolonging the GRT of 
therapeutic agents is thought to be beneficial especially under several circumstances such as for 
drugs acting topically on the gastric region, for drugs with a narrow therapeutic window or for 
drugs with the major absorption site in the upper GI tract (5-6). 
S.A. Modiet al (2011)12:The objective of the present study is to prepare sustained release drug 
delivery system based on thematrix tablet for the freely water soluble drug Metoclopramide 
hydrochloride in order to achieve greater patient compliance. The sustained release formulations 
were prepared by using natural polymers like Dextrin, Guar gum and Xanthan gum. The 
formulations, with individual polymers were prepared in Drug: polymer ratio varying from 1:1:1 
to 1:2:2 in the form of matrix tablet using wet granulation method. The formulations were 
subjected to in-vitro dissolution test studies for 10 hour. In-vitro dissolution studies were carried 
out in pH 1.2 and pH 6.8.Among all the formulations, the formulation F10 and F12, which 
contained Drug: Guar gum: Xanthan gum in the ratio 1:2:1 and 1:2:2 respectively, showed desire 
drug release rate up to 10 hour. 
Indranil Kumar Yadavet al (2010)13:The objective of the present study was to develop the oral 
sustained release matrix tablets of aceclofenac using hydrophilic and hydrophobic polymers. 
Aceclofenac is a non steroidal anti-inflammatory agent used in symptomatic treatment of 
rheumatoid arthritis, osteoarthritis and ankylosing spondylitis and its biological half life is 4 hrs. 
FTIR studies were carried to know the interaction between the drug and polymer. Controlled 
release formulations of aceclofenac (200 mg) were prepared by direct compression method. The 
tablets were subjected to physicochemical, invitro drug release and stability studies. 
Optimization of the formulation was done by studying effect of drug to polymer ratio on drug 
release. FTIR studies indicated absence of any interaction between aceclofenac and polymers. 
The physicochemical properties of tablets were found within the limits. The drug release from 
optimized formulations F1, F4 and F7 was extended for a period of 12 hrs. The kinetic treatment 
to optimized formulations showed that the release of drug follows zero order model and Super 
Case II transport for F1 and F7 while the drug release of F4 was best explained by Higuchi’s 
model and Super Case II transport. Release of the drug was retarded with increase in polymer 
concentrations. The optimized formulations were subjected to stability studies for three months 
at 45° temperature with RH 75±5%, and showed stability with respect to 
physicochemicalparameters and release pattern. Results of the present study indicated the 
suitability of hydrophilic and hydrophobic polymers in the preparation of matrix based sustained 
release formulation of aceclofenac. 
R.Charulathaet al (2012)14:Carbamazepine is a widely used anti-epileptic drug in the therapy of 
psychomotor seizuresand trigeminal neuralgia. The objective of the present study is to prepare 
oral controlled release matrix tablet of carbamazepine (420 mg) by wet granulation technique 
using hydrophilic polymers such as HPMC, Sodium CMC of various concentrations. Its 
solubility was increased by making a complex with β –cyclodextrin thereby increasing its 
bioavailability. Eudragit incorporated as a release modifier due to its solubility in acidic medium. 
The tablets were evaluated for preformulation studies like angle of repose, bulk density, 
compressibility index and physical characteristics like hardness, weight variation, friability and 
drug content. In-vitro release of drug was performed in 0.1 N HCl for 2 hours PBS pH6.8 for 12 
hours. All the physical characters of the fabricated tablet were within acceptable limits. In vitro 
release profile of marketed controlled release formulation (tegretol) showed the drug release 84% 
in 12th hour,where as our selected formulations F13 (HPMCK4m) released at 88% of drug in 
12th hour respectively. The relative bioavailability of the selected formulation was 0.435 μg/ml 
of tmax at 12 hr compared with marketed product of 0.369μg/ml. The stability studies showed 
that it followed zero order kinetics when fitted to kinetic models (Higuchi, Hixson and Peppas).It 
was clear from the dissolution profile of carbamazepine from matrix tablets prepared using 
different polymers were indicated an increase in the polymer ratio retarded the drug release to a 
greater extent. As a concluding remark, F13 carbamazepine matrix tablet showed better oral 
bioavailability than the marketed tablet, and further animal studies/human studies could be under 
taken with large number of subjects in order to confirm these results. 
V.C. Modiet al (2010)15:Sustained releases tablets of Diltiazem hydrochloride were formulated 
by employing hydroxypropyl methylcellulose (HPMC K100 M) and the sustained release 
behaviour of the fabricated tablets was investigated. Sustained release matrix tablets containing 
120 mg Diltiazem hydrochloride were developed using different drug: polymer (HPMC K100 
M) ratios. Tablets were prepared by wet granulation technique. Formulation was optimized on 
the basis of acceptable tablet properties and invitro drug release. The resulting formulation 
produced robust tablets with optimum hardness, consistent weight uniformity and low friability. 
All tablets but one exhibited gradual and near-complete sustained release for Diltiazem 
hydrochloride (96-100%) at the end of 24 h. The results of dissolutionstudies indicated that 
formulation B5 (drug to polymer 1:1.25) was found to be most successful as it exhibits drug 
release pattern very close to theoretical release profile. A decrease in release kinetics of the drug 
was observed on increasing polymer ratio. 
Kamlesh J. Wadheret al (2011)16:Metformin hydrochloride is recommended globally as first 
line therapy due to its favorable profile on morbidity and mortality associated with type-2 
diabetes mellitus. However, limitations of multiple dosing and risk of triggering gastrointestinal 
symptoms make its dose optimization difficult. Extended-release metformin matrix tablets were 
prepared by direct compression of drug and different pH-dependent (Eudragit L-100 and S-100) 
and pH-independent (Eudragit RLPO and RSPO) polymer combinations. The influence of 
varying the polymer/polymer (w/w) ratio was evaluated. Among the different examined polymer 
blends, matrix tablets based on S-100/RLPO and S-100/RSPO mixtures gave the more sustained 
release pattern. The excipients used in this study did not alter physicochemical properties of the 
drug, as tested by Fourier transform Infrared Spectroscopy and the thermal analysis using 
differential scanning calorimetry. All the batches were evaluated for thickness, weight variation, 
hardness, and drug content uniformity. The in vitro drug dissolution study was carried out using 
USP 22 apparatus II, paddle method and the release mechanisms were explored. Mean 
dissolution time is used to characterize drug release rate from a dosage form and indicates the 
drug release retarding efficiency of polymer. Kinetic modeling of in vitro dissolution profiles 
revealed the drug release mechanism ranges from diffusion controlled to anomalous type. Fitting 
the data to Korsmeyer equation indicated that diffusion along with erosion could be the 
mechanism of drug release. 
R. Gendleet al (2010)17: The objective of this work was to develop sustained release tablets of 
highly water soluble Tramadol HClusing polymers (HPMC K100M, HPMC K15M, HPMC K 
4M) as cost effective, non toxic easily available and suitablehydrophilic matrix system. 
Sustained release tablet of Tramadol HCl (dose 50mg) were produced by wet granulationmethod. 
After the evaluation of physical characteristics of tablets. The dissolution test was performed in 
0.1 N HCl fortwo hr. and phosphate buffer pH 6.8 for ten hr. The release profile remains 
unchanged after three months storage oftablets. The best fit release kinetics was achieved with 
the zero order plot followed by the Higuchi and Korsmyer andPeppas equation. The data 
obtained proved that the formulations are useful for a sustained release of Tramadol HCl dueto 
the percentage released after 12 hr. is nearly to 100%. 
Suresh V Kulkarni43 et al., (2010)20:investigation an attempt was made to reduce 
thefrequencyof dose administration and to improve the patient compliance by 
developingcontrolled release (CR) matrix tablet of Stavudine using naturally occurring (Guar 
gum and Xanthun gums) and Synthetic Polymers( HPMC and Ethylcellulose). Six batches of 
CRmatrix tablets of Stavudine were developed by usingwet granulation technique. Tablets were 
evaluated for weight variation, hardness,friability and In vitro dissolution studies. All 
formulation showed compliance withpharmacopoieal standards. Among the six formulations, F3 
showed controlled release of drug for 12 hours with 91.65% drug release. The release data was 
fitted to various mathematical models such as, Higuchi, Korsmeyer-Peppas, First-order, and 
Zeroorder to evaluate the kinetics and mechanism of the drug release was found to bediffusion 
coupled with erosion. 
RaghavendraRao N.et al., (2009)21:was to develop sustained release matrix tablets of water 
soluble Tramadol hydrochloride using different polymers viz.Hydroxy propyl methyl cellulose 
(HPMC) and natural gums like Karaya gum (KG)and Carrageenan (CG). Varying ratios of drug 
and polymer like 1:1 and 1:2 wereselected for the study. After fixing the ratio of drug and 
polymer for control therelease of drug up to desired time, the release rates were modulated by 
combinationof two different rates controlling material and triple mixture of three different 
ratecontrolling material. After evaluation of physical properties of tablet, the in vitro release 
study was performed in 0.1N HCl pH 1.2 for 2 hrs and in phosphate buffer pH 6.8 up to 12 hrs. 
The effect of polymer concentration and polymer blendconcentration were studied. Different 
ratios like 80:20, 60:40, 50:50, 40:60 and 20:80were taken. Dissolution data was analyzed by 
Korsmeyer-Peppas power lawexpression and modified power law expression. It was observed 
that matrix tabletscontained polymer blend of HPMC/CG were successfully sustained the release 
ofdrug upto 12 hrs. Among all the formulations, formulation F16 which contains 20%HPMC 
K15M and 80% of CG release the drug which follow Zero order kinetics via, swelling, diffusion 
and erosion and the release profile of formulation F16 was comparable with the marketed 
product. Stability studies (40±2ºC/75±5%RH) for 3months indicated that Tramadol 
hydrochloride was stable in the matrix tablets. TheDSC and FTIR study revealed that there was 
no chemical interaction between drugand excipients. 
 
Jolly M. Sankalia49 et al., (2008)22:examined in vitro–in vivo correlation for 
glipizidehydrophilic sustained-release matrices tablets on various polymers like ethyl cellulose, 
microcrystalline cellulose, hydroxyl propyl methylcellulose, xanthan gum,guar gum, Starch 
1500, and lactose on in vitro release profiles was studied and fittedto various release kinetics 
models. 
Alok Rayet al (2003)23:studied the role of modulating factors such as drug topolymer ratio, drug 
loading, particle size, and compaction pressure ant amount oflubricant on release Caffeine from 
tamarind seed polysaccharide, which is forhydrophilic matrix for drug delivery system. The 
following observation on releaserate were made using Korsmeyer–Peppas's and Higuchi's 
equations I) thecompaction pressure had no significant effect on release. ii) the effect of particle 
sizepolysaccharide on release was insignificant except in the range of 250-150 microns.iii) the 
increase in polymer content showed decreases in both rate of release anddissolution. Iv) the 
increase in drug loading showed the rate of release anddissolution decreased. v) the presence of 
lubricant up to 2% had no effect on the rateof release. The mechanism of release was found to be 
anomalous (n>0.5) in all thecases. 
 
Jordanet al25 “Metoclopramide HCl showed controlled release behavior when embedded in a 
hydrophilic matrix of chitosan and sodium alginate. The in vitro release data was found to be 
first order according to the Higuchi mechanism. An in vivo evaluation of the metoclopramide 
controlled release matrix on six male volunteers was carried out. The plasma samples were 
analyzed using a high-performance liquid chromatography (HPLC) method using a mobile phase 
of acetonitrile:acetic acid (30:70), with the pH adjusted to 4.7, a reverse phase Hypersil BDS 
Phenyl column (4 μm, 250×4 mm) and the detection was performed at 305 nm. The controlled 
release formula was found to be effective in delaying absorption (tmax 4.5 h as compared to 
1.2 h), reducing the peak plasma concentrations (Cmax 63.4 ng/ml as compared to 95.9 ng/ml) and 
maintaining higher concentrations during the elimination phase when compared to the immediate 
release formula. This proves the suitability of the suggested system for further studies.” 
 
Monica R P Rao et al26 “Metoclopramide HCl is mainly used as an anti-emetic agent in the 
cancer chemotherapy. It alsostimulates the upper GI tract and is used in the management of some 
forms of nausea, vomiting and pain associated withmigraine as well as in gastric stasis where 
quick onset of action is required. Conventional tablet may give delayed onset of action (probably 
1.5-2 hrs) which may be over come by administering immediate release tablets. The 
development of immediate release tablet formulations is based on the use of super 
disintegrantsseparately or in combination. Seven formulations were prepared using simplex 
centroid mixture design where sodium starch glycolate (X1), cross carmellosesodium (X2) and 
pregelatinised starch (X3) were selected as independent variables and dependent variables were 
disintegration time (Y1) and release at 15 minutes (Y2). Response surface plots were drawn, and 
optimum formulations were selected by grid search method. X1, X2 and X3 when used 
individually gave satisfactory results but when used in combination gave better results. The 
results showed a good relationship between the experimental and predicted values, which 
confirms the predictability of the model.” 
 
R F Thoeni et ai27 “The value of orally administered metoclopramide hydrochloride to enhance 
bowel opacification during abdominal and pelvic computed tomography (CT) was analyzed 
prospectively in 202 patients in a control group and 334 patients in an experimental group who 
received 10 mg of metoclopramide with the first dose of oral contrast material. Five hundred 
milliliters of 2% sodium diatrizoate was given orally 45-60 minutes and 30 minutes before the 
study, and 250 mL was given 5-10 minutes before the study. Opacification of stomach, 
duodenum, and small and large bowels was graded from 0 to 3+, and the presence of 
pseudotumors or side effects from metoclopramide were noted. No significant difference was 
found in the opacification of stomach, duodenum, and jejunum between control and experimental 
studies. Opacification was significantly better in metoclopramide studies than control studies in 
the proximal ileum (P less than .05), distal ileum (P less than .05), right colon (P less than .05), 
and transverse colon (P less than .05). Pseudotumors were seen in 7% of control and 3% of 
experimental subjects. No side effects were encountered. Routine oral administration of 
metoclopramide before abdominal and pelvic CT examinations is recommended for rapid 
opacification of the ileum and proximal colon for all outpatients and for inpatients who must 
undergo CT on an emergency basis.” 
 
V. F. Patel et al (2007)24studied the influence of viscosity of hydroxypropyl methyl cellulose 
and types of filler on Dipyridamole release from floating matrix tablet using 3 full factorial 
design. Multiple regression analysis was performed for the dependant variables. To evaluate 
contribution of the factors with their levels two way ANOVA was performed followed by Tukey 
test. Polynomial equations and response surface plots were generated for all dependant variables. 
It was observed that both the factors had significant influence on all dependant variable studied. 
It was observed as the viscosity of polymer increases the release rate constant was decreased. 
Release rate obtained was highest when microcrystalline cellulose was employed as filler 
followed by dicalcium phosphate and lactose. Mechanism of release was anomalous type and 
depends upon viscosity of polymer and types of filler used. A major controlling factor for 
kinetics of drug release was viscosity of polymer and it can be modified by incorporation of 
different types of filler. 
 
Santanu Ghosh41 et al., (2010)18: was to develop matrix tablets for oral controlledrelease of 
aceclofenac. Matrix tablets of aceclofenac, using various viscosity of hydrophilic polymer 
HPMC in two different proportions, hydrophobic polymer ethylcellulose and Guar gum were 
prepared by wet granulation method and subjected toin vitro drug release studies. Based on the 
results of the in vitro studies, it wasconcluded that the HPMC matrix tablets provided oral 
controlled release ofaceclofenac. 
 
SantanuGhosh and Barik42 et al., (2010)19: was to develop matrix tablets for oral controlled 
release of aceclofenac using ethyl cellulose, guar gum, and various gradesof cellulose 
polymers.The release profile of one of the formulated aceclofenactablets, which 
containedhydroxypropyl methyl cellulose, was statistically similar tothat of the commercial 
aceclofenac brand in all the dissolution media. The resultindicate that it is feasible to achieve a 
stable once daily sustained release aceclofenactablet formulation by using HPMC k4M of 
4000cps viscosity grade as matrixmaterial. 
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9 The prokinetic activity of metoclopramide is mediated by muscarinic activity, D2 receptor 
antagonist activity and 5-HT4 receptor agonist activity.[4][5] The prokinetic effect itself may also 
contribute to the anti-emetic effect. 
Adverse Effect33,34,35: 
¾ Common adverse drug reactions (ADRs) associated with metoclopramide therapy include: 
restlessness, drowsiness, dizziness, lassitude, and/or dystonia. Infrequent ADRs include: 
headache, extrapyramidal effects such as oculogyric crisis, hypertension, hypotension, 
hyperprolactinaemia leading to galactorrhoea, constipation, and/or depression. Rare but serious 
ADRs associated with metoclopramide therapy include: agranulocytosis, supraventricular 
tachycardia, hyperaldosteronism, neuroleptic malignant syndrome, akathisia and/or tardive 
dyskinesia.[7] Dystonic reactions are usually treated with benztropine or procyclidine. 
¾ The risk of extrapyramidal effects is increased in young adults (<20 years) and children, and 
with high-dose or prolonged therapy.[6][7] Tardive dyskinesias may be persistent and 
irreversible in some patients. 
¾ In 2009, the U.S. Food and Drug Administration required all manufacturers of metoclopramide 
to issue a black box warning regarding the risk of tardive dyskinesia with chronic or high-dose 
use of the drug.[11] 
 
 
 
 
 
 
 
 
 EXCIPIENT PROFILE 
 
1.MICROCRYSTALLINE CELLULOSE36: 
  
¾ Synonym:Cellulose gel, crystalline cellulose, Avicel PH 101, 102  
¾ Empirical Formula: (C6H10O5)n 
¾ Molecular weight:Approx.36000  
¾ Description: Purified, partially depolymerised cellulose occurs as a white, odorless, 
tasteless, crystalline, powder composed of porous particles  available in different particle 
size grades with different properties , i.e. 101 ,102 
¾ Bulk Density: 0.28gm/cm 3 
¾ Tapped Density: 0.43gm/cm3 
¾ Solubility: Insoluble in water, dilute acids and most organic solvents .Slightly soluble in 
sodium hydroxide solution. 
¾ Stability and storage condition:  Stable and hygroscopic. Store in a well – closed 
container.  
¾ Incompatibility: None cited in the literature. 
¾ Handling precautions: No restrictions. 
¾ Uses: Tablet binder / diluent (5-20%), tablet disintegrant (5-15%), tablet glidant (5-15%) 
antiadherent (5-20%), capsule diluents (10-30%). 
2.MANNITOL37 
¾ Chemical name:hexanitromannitol 
¾ Synonym: mannitolhexanitrate, nitromannite, nitromannitol, nitranitol, mannitrin 
¾ IUPAC: (2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol-1,2,3,4,5,6-hexanitrate 
¾ Molecular formula: C6H8N6O18 
¾ Molar mass: 452.15712 
¾ Density: 1.604 g/cc 
¾ Melting point: 112 °C = 234 °F 
¾ Formula:C6H14O6 
¾ Mol. mass:182.172 
¾ Use: This polyol is used as an osmotic diuretic agent and a weak 
renalvasodilatorMannitol is also the first drug of choice for the treatment of acute 
glaucoma in veterinary medicine. It is administered as a 20% solution IV. It dehydrates 
the vitreous humor and, thus, lowers the intraocular pressure. However, it requires an 
intact blood-ocular barrier to work. Mannitol can also be used to temporarily encapsulate 
a sharp object (such as a helix on a lead for an artificial pacemaker) while it is passed 
through the venous system. Because the mannitol dissolves readily in blood, the sharp 
point will become exposed at its destination.Mannitol may be administered in cases of 
severe Ciguatera poisoning. Severe ciguatoxin, or "tropical fish poisoning" can produce 
stroke-like symptoms. Mannitol is the primary ingredient of Mannitol Salt Agar, a 
bacterial growth medium, and is used in others. In oral doses larger than 20 g, mannitol 
acts as an osmotic laxative, and is sometimes sold as a laxative for children 
 
3.HYDROXY PROPYL METHYL CELLULOSE38 
 
¾ Synonym: Benecel MHPC; E464; hydroxypropyl methylcellulose; 
HPMC;hypromellosum; Methocel; methylcellulose propylene glycol ether; methyl 
hydroxypropylcellulose; Metolose; MHPC; Pharmacoat; Tylopur; Tylose MO. 
¾ Nonproprietary Name: BP: Hypromellose JP: HypromellosePhEur: Hypromellose USP: 
Hypromellose 
¾ Empirical Formula: CH2CH(OH)CH3. 
¾ Molecular Weight: 591.3 
¾ Description: Fine, white, precipitated or milled, impalpable powder of low bulk density. 
Odour and taste are slight but characteristic. The powder is readily adheres to the skin.    
¾ Density, bulk: 0.519 gm/cm3 
¾ Density, tapped:   0.286gm/cm3 
¾ Melting point: 117-1500C 
¾ Stability And Storage Condition : Stable, non self polymerisable, store in cool and dry 
place in a well closed container. 
¾ Incompatibilities:  Incompatable with strong acid substances, alkaline substances, iron 
salts, avoid mixing with strong oxidizing materials .Use  with caution with drugs , which 
are incompatible with alkali. 
¾ Uses: POLYMERt, glidant or antiadherent (0.25-2.0%). 
 
4.MAGNESIUM STEARATE39 
¾ Synonym: Metallic stearate; octadecanoic acid; magnesium salt; Stearic acid. 
¾ Nonproprietary Name: Magnesium Stearate (BP); Magnesium Stearate (JP); Magnesium 
Stearate(USP). 
¾ Empirical Formula: C36H70MgO4 
¾ Molecular Weight: 591.3 
¾ Description: Fine, white, precipitated or milled, impalpable powder of low bulk density. 
Odour and taste are slight but characteristic. The powder is readily adheres to the skin.    
¾ Density, bulk: 0.519 gm/cm3 
¾ Density,tapped:   0.286gm/cm3 
¾ Melting point: 117-1500C 
¾ Stability And Storage Condition : Stable, non self polymerisable, store in cool and dry 
place in a well closed container. 
¾ Incompatibilities:  Incompatable with strong acid substances, alkaline substances, iron 
salts, avoid mixing with strong oxidizing materials .Use  with caution with drugs , which 
are incompatible with alkali. 
¾ Uses:  tablet and capsule lubricant, glidant or antiadherent (0.25-2.0%). 
 
5.Carboxymethylcellulose Sodium40 
¾ Nonproprietary Names: Carmellose Sodium  
¾ Synonyms: Akucell, Aqualon CMC, Aquasorb, Blanose, Carbose D, carmello- sum 
natricum, Cel-O-Brandt,cellulose gum, Cethylose, CMCsodium, E466; Finnfix, 
Glykocellan, Nymcel ZSB; SCMC; sodium carboxymethylcellulose; sodium cellulose 
glycolate; Sunrose; Tylose CB; Tylose MGA; Walocel C; Xylo-Mucine. 
¾ Chemical Name and CAS Registry Number :Cellulose, carboxymethyl ether, sodium salt  
¾ Functional Category: Coating agent; stabilizing agent; suspending agent; tablet 
andcapsule disintegrant; tablet binder; viscosity-increasing agent; water-absorbing agent. 
¾ Applications in Pharmaceutical Formulation :Carboxymethylcellulose sodium is widely 
used in oral and topicalpharmaceutical formulations, primarily for its viscosity-increasing 
properties. Viscous aqueous solutions are used to suspend powders intended for either 
topical application or oral and parenteral administration.Carboxymethylcellulose sodium 
may also beused as a tablet binder and disintegrant, (3–6)and to stabilizeemulsions. (7,8) 
Higher concentrations, usually 3–6%, of the medium viscositygrade are used to produce 
gels that can be used as the base forapplications and pastes; glycols are often included in 
such gels to 
¾ Density (bulk): 0.52 g/cm3 
¾ Density (tapped): 0.78 g/cm3 
¾ Dissociation constant pKa : 4.30 
¾ Melting point: Browns at approximately 2278C, and chars at approximately 2528C. 
¾ Moisture content :Typically contains less than 10% water.However, 
carboxymethylcellulose sodium is hygroscopic and absorbs significant amounts of water 
at temperatures up to 378C at relative humidities of about 80%.  
¾ Solubility :Practically insoluble in acetone, ethanol (95%), ether, and toluene. Easily 
dispersed in water at all temperatures, forming clear, colloidal solutions. The aqueous 
solubility varieswith the degree of substitution (DS).Viscosity Various grades of 
carboxymethylcellulose sodium are commercially available that have differing aqueous 
viscosities, Aqueous 1% w/v solutions with viscosities of 5–2000mPa s (5–2000 cP) may 
be obtained. An increase in concentration results in an increase in aqueous solution 
viscosity.  
¾ Stability and Storage Conditions:Carboxymethylcellulose sodium is a stable, though 
hygroscopicmaterial. Under high-humidity condtions, carboxymethylcellulose sodium 
can absorb a large quantity (>50%) of water. In tablets, this has been associated with a 
decrease in tablet hardness and an increase in disintegration time. 
¾ Incompatibilities: Carboxymethylcellulose sodium is incompatible with strongly acidic 
solutions and with the soluble salts of iron and some other metals, such as aluminum, 
mercury, and zinc. It is also incompatible with xanthan gum. Precipitation may occur at 
pH < 2, and also when it is mixed with ethanol (95%). Carboxymethylcellulose sodium 
forms complex coacervates with gelatin and pectin. It also forms a complex with 
collagen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM AND OBJECTIVES 
 
¾ The aim of the present study was to develop the oral sustained release matrix tablets of 
Metoclopramide using hydrophobic polymers. 
¾ These dosage forms are designed to deliver the drug at a controlled and predetermined 
rate, thus maintaining a therapeutically effective concentration of the drug in the systemic 
circulation for a long period of time. 
¾ To increase duration of action. 
¾ To achieve better patient compliance. 
¾ To maintain steady state concentration of drug in plasma. 
¾ To reduce dosing frequency. 
¾ Cost effective. 
PLAN OF WORK 
¾ Literature survey. 
¾ Procurement of drug and polymer substances. 
¾ Preformulation studies. 
¾ Preparation of Std. Curves of Metoclopramide HCL  
¾ Formulation development of SR tablet. 
¾ Evaluation of SR tablet for 
¾ Extended evaluation & optimize batch ( drug release kinetic std.) 
¾ Stability studies of the optimized batch. 
  
MATERIALS AND METHODS 
 
 
Table -1Materials and manufacturer 
 
 
Sr.No. 
 
Materials 
 
Monograph 
 
Manufactures 
1. Metochlopramide Hydrochloride IP/BP/USP Mission Vivacare Limited 
2. Microcrystalline cellulose IP Reliance cellulose (P) Ltd. 
3. Mannitol IP Signet Pharma 
4. Hydroxyl propyl methyl cellulose IP R A Chemicals 
5. Sodium carboxyl methyl cellulose  BP FMC ,Ireland 
6. Magnesium stearate IP VasundharaRasayans ltd. 
 
 
Table -2Equipments used in the formulation 
Sr.No. Instruments Manufacturer 
1 Electronic Balance 
Shimadzu Corporation AW 
220 and BX 6205 
2 Tray Dryer Erweka Pvt. Ltd. 
3 Dissolution Apparatus (USP) Electrolab Pvt. Ltd 
4 High Performance Liquid Chromatography Agilent Ltd. 1100 
5 Tablet Hardness tester Vankel Ltd. K200 
 PREFORMULATION 
Preformulation is a branch of pharmaceutical sciences that utilizes biopharmaceutical principles in the 
determination of physiochemical properties of a drug substance. The goal of pre-formulation studies is 
to choose the correct form of the substance, evaluate its physical properties and understanding of the 
material’s stability under various conditions, leading to the optimal drug delivery system. The 
preformulation study focuses on the physiochemical parameters that could effect the development of 
efficacious dosage form. These properties may ultimately provide a rationale for formulation design. 
Also it will help in minimizing the problems in later stages of drug development, reducing drug 
development costs decreasing products time to market. It gives the information needed to define the 
nature of the drug substance and provide framework for the drug combination with pharmaceutical 
excipients in the dosage form.    
 
Objective:         
 The overall objective of preformulation testing is to generate information useful to the formulation in 
developing stable and bioavilable dosage form. 
Preformulation encompasses at least following test. 
 
6 Friability test apparatus Electrolab Pvt. Ltd EF 2 USP 
7 Ultra Violet Visible Spectrophotometer 
Shimadzu Corporation UV- 
1700 
8 FTIR Spectrometer Shimadzu Corporation, 8400S 
9 Tap density Apparatus Erweka Pvt. Ltd 
10 Granulate Flow Tester Erweka Pvt. Ltd 
11 Vernier Caliper Digimatic 
12 pH Meter, Systronics(335) 
13 LOD apparatus Sartorius 
I) Bulk Characterization:          
• Crystalline And Polymorphism, hygroscopicity. 
• Powder properties (flow, compaction, density, particle size, surface area etc.) 
• Microscopy (morophology, particle characteristics) 
• Molecular spectroscopy (FT-IR) 
II) Solubility Analysis:         
• Ionization constant (pka) 
• PH solubility profile 
• Common ion effect 
• Thermal effect on solubility 
• Solubilization 
• Partition coefficient (logP or logD) 
• Dissolution 
III) Stability Analysis: 
• Stability (heat, light, base, acid, oxidizer) 
• Solution stability 
• Solid-state stability 
• Excipient compatibility 
 
Identification of drug 
 
The identification of drug was done by IR Spectroscopy. 
Method: Triturate 1-2 mg of the substance to be examined with 300-400 mg, unless otherwise specified, 
of finely powdered and dried potassium bromide R or potassium chloride R. These quantities are 
usually sufficient to give a disc of 10-15 mm diameter and a spectrum of suitable intensity. Infrared 
spectrometers are used for recording spectra in the region of 4000-650 
Preformulation stability studies are usually the first quantitative assessment of chemical stability of a 
drug as well as stability in presence of other excipients. The primary objectives of this investigation are 
identification of stable storage conditions for drug in the solid state and identification of compatible 
excipients for a formulation.  
 
For drug excipients compatibility study selected excipients given below:- 
 
Table -3 Drug –excipients compatibility study: 
 
Sr.no. Excipients Properties 
1. Microcrystalline cellulose Diluents 
2. Mannitol Diluents 
3. Hydroxyl methyl propyl 
cellulose 
Polymer 
4. Sodium Carboxyl methyl 
cellulose  
Polymer 
5. Magnesium stearate Glidant 
 
According to the functional category these excipients were mixed in the different ratio. These mixtures 
were kept at 300C +65% RH, and 400C+75%, in a 2ml glass vial in exposed condition for 1 month. 
At interval of 4 weeks, the sample was withdrawn and subjected for analysis and related substances. At 
the interval of 2 week, the samples were withdrawn and given to analytical development for analysis of 
following parameters: 
• Moisture content  
• Assay 
• Related Substances   
 
 
Table .4 PHYSICAL OBSERVATION OF COMPATIBILITY STUDY: 
 
Drug & Excipients 
(Ratio 1:1) 
Observation Result 
Initial 300 C/65% 
RH after 30 
days 
400 C/75% 
RH after 
30 days 
Metoclopramide 
Hydrochloride 
White to off 
white 
powder 
White to off 
white 
powder 
White to 
off white 
powder 
Compatible 
Metoclopramide Hcl 
          + 
HPMC 
White to off 
white 
powder 
White to off 
white 
powder 
White to 
off white 
powder 
Compatible 
Metoclopramide Hcl 
           +  
Sodium CMC 
White to off 
white 
powder 
White to off 
white 
powder 
White to 
off white 
powder 
Compatible 
Metoclopramide Hcl 
           + 
Mannitol 
White to off 
white 
powder 
White to off 
white 
powder 
White to 
off white 
powder 
Compatible 
Metoclopramide Hcl 
           +   
Microcrystalline 
Cellulose 
White to off 
white 
powder 
White to off 
white 
powder 
White to 
off white 
powder 
Compatible 
Metoclopramide Hcl 
          + 
Mg Stearate  
White to off 
yellow 
powder 
White to off 
yellow 
powder 
White to 
off yellow 
powder 
White to off white 
powder 
 
Based on results following excipients were used to fabricate robust formulation of Metoclopramide Hcl 
sustained release matrix tablets.  
Table 5Selected excipients for prototype formulation: 
 
 
 
 
 
 
 
 
 
 
Evaluation of Metoclopramide Hcl sustained release matrix tablets 
 
1) Angle of repose41:  it was measured by fixed funnel. The fixed funnel method employ a funnel that 
was secured with its tips at a given height H, above graph paper that was placed on a flat horizontal 
surface. Granules were carefully poured through the funnel until the apex of the conical pile just 
touches the tips of the funnel. Thus, with R being the radius of the base of the conical pile.                                                
 
Tan θ =H/R   
                                 Where,  
    θ = angle of repose     
             H =Height of pile 
             R = Radius of pile    
Sr. no. Excipients Category 
        1. Microcrystalline cellulose Diluents 
        2. 
Mannitol 
Diluents 
        3. Hydroxyl methyl propyl 
cellulose 
Polymer 
        4. Sodium Carboxyl methyl 
cellulose  
Polymer 
        5. Magnesium stearate Glidant 
Table  6 Angle of Repose 
 
ANGLE OF REPOSE PROPERTIES 
25-30 Excellent 
31-35 Good 
36-40 Fair 
41-45 Passable 
46-50 Poor 
51-55 Very poor 
>56 Extremely poor 
 
 
 2) Determination of tap density and bulk density41: An accuratelyweighed quantity of the powder 
(W), was carefully poured into the graduated cylinder and the volume (V0) was measured. Then the 
graduated cylinder was closed with lid, set in to the density determination apparatus, (Erweka Pvt. Ltd). 
The density apparatus was set for 100 taps and after that the volume (Vf) was measured and continued 
operation till the two consecutive readings were equal. The bulk density, and tapped density were 
calculated using the following formulas,                                                     
 
       Bulk density       =    W/Vo 
Tapped density   =   W/ Vf 
                                      Where, 
 W = weight of powder  
Vo = Initial volume 
Vf = final volume   
3) Compressibility index (Carr index)41:                                                                                                                           
Compressibility index is an important measure that can be obtained from the bulk and tapped 
densities.carrs index a material having values of less than   15 to 20 % is defined as the free flowing 
material.  
Ci=    ( V0- Vf)   × 100 
Vo 
 
Table  7Compressibility index 
 
%Compressibility index Properties 
5 – 12 Free flowing 
12 – 16 Good 
18 – 21 Fair 
23 – 35 Poor 
33  - 38 Very poor 
>40 Extremely Poor 
 
 
4)Hausner Ratio41: It indicates the flow properties of the powder and is measured by the ratio of 
tapped density to bulk density. 
Hausner ratio =tapped density/ bulk density 
 
 
 
 
Table  8Hausner ratio 
 
Sr. No Hausner ratio Property 
1 0-1.2 Free flowing 
2 1.2-1.6 Cohesive powder 
 
 
5) Sieve analysis: the main aim of sieve analysis is to determine the different size of particles present. 
A series of standard sieves were stacked  one above the other so that sieves with larger pore size ( less 
sieve number) occupy top position followed by sieves of decreasing pore size (larger sieve number) 
towards the bottom 
Procedure: A series of sieves were arranged in the order of decreasing pore diameter. (Increasing in 
sieve number) i.e. sieve numbers #20, #40, #60, #100. 100gm of drugs were weighed accurately and 
transferred to sieve #20 which kept on top. The sieves were shaken for about 5 minutes. Then the drug 
retained on each sieve were taken, weighed separately and expressed in terms of percentage. 
 
6) L.O.D. :( loss on drying) of granules- the main aim of LOD of granules is to find out the presence 
of moisture content. 
Procedure: LOD of granules was determined by using I.R. moisture balance (Sartorius).Required 
amount of granules was placed on I.R. plate and temperature was maintained at 1050 C for 5 minutes. 
(Limit of moisture contained was 1.6%). 
EVALUATION OF TABLET: 
 
Description: Uncoated oval shaped embossed tablets were prepared. Check a representative sample for 
the above description.  
 
1) Tablet dimensions41,43: Thickness and diameter were measured using a calibrated dial calipers. Ten 
tablets of each formulation were evaluated. 
2) Hardness43: Monsanto hardness tester was used to evaluate hardness of tablet. The tester consists 
of a barrel containing a compressible spring held between two plungers. The lower plunger was placed 
in contact with the tablet, and a zero reading was taken. The upper plunger was then forced against a 
spring by turning a threaded bold until the tablet fractures. As the spring compressed, a pointer rides 
along a gauge in the barrel to indicate the force .The force of fractured recorded, and the zero force 
reading was deducted it. Ten tablet of each formulation were evaluated. 
3) Friability41,42,43: weigh accurately 20 tablets and place them in the friability test apparatus. Adjust 
the timer to 4 minutes. Operate the apparatus at 25 ±1 rpm and observe the tablets while rotating .No 
tablet should be stick to the walls of apparatus. Take the tablet out and observe. No capping should be 
observed. Weigh the tablet, after dedusting excess powder from their surface.  
 Calculation: calculate the Friability in % using formula:- 
                                    Friability = (W1-W2) ×100 
  W1 
                                 Where, 
                                             W1= Initial weight of tablet taken, 
                                             W2=final weight of tablet after testing. 
4) Weight variation44,47,48: Twenty tablets were selected randomly. Tablets were weighed individually 
and average weight was calculated. Then deviation of each tablet from average weight was calculated 
and percent deviation was computed. Standard deviation was compared with the U.S.P. limit.   
               Table  9  U.S.P. weight variation limit of uncoated tablet: 
 
Average weight of tablet Percentage deviation 
130 or less 
130-324 
More than 324 
10 
7. 5 
5 
 5)Standard Calibration Curve For Metoclopramide Hcl :100mgmetoclopramide hydrochloridewas 
dissolve in 100ml of 0.1N Hcl. From the stock solution aliquots of 10, 20,30,40,50, 60, 70, 80, 90, 
100ml were pipette out and made up to 100ml with 0.1N Hcl. The absorbance of above solution was 
measured at 306 nm by U.V. spectrophotometer. The standard graph was plotted.  
 
6) AssayFor Metoclopramide Hcl45,46 -Weigh and powder 20 tablets. Weigh accurately a quantity of 
the powder equivalent to 10 mg of anhydrous metoclopramide hydrochloride, add 50 ml of 0.1M 
hydrochloric acid, heat on a water-bath at 70o for 15 minutes, cool, dilute to 100.0 ml with water and 
filter. To 20.0 ml of this solution add 15 ml of 1.25M sodium hydroxide and extract with three 
quantities, each of 30 ml, of chloroform, dry each extract with anhydrous sodium sulphate and filter. 
Dilute the combined extracts to 100.0 ml with chloroform and mix. Measure the absorbance of the 
resulting solution at the maximum at about 305 nm 
 
7) Stability study49,50,51:An ethical drug manufacturer is committed to provide to his consumers drug 
products, which are efficacious and safe. This can be ensured only by instituting a sound programme to 
study the stability of a product during its various phases of development and to arrive at the proper 
storage condition and the expiry period under those conditions. This is a requirement in most of the 
countries and is stipulated by the regulatory agencies of those countries. These studies would very 
quickly identify the need, if any, to stabilize the active substance or the formulation, and invaluable 
time and effort from being spend on marketable formulation. With the recent trend towards 
globalization of manufacturing operation, it is imperative that the final product be sufficiently rugged 
for marketing worldwide under various climatic conditions including tropical, subtropical temperature. 
Metoclopramide Hcl sustained release matrix tabletsformulated in the present study were subjected to 
accelerated stability studies. The stability studies of formulated tablets were carried out at 400 C, RH 
75% and at room temperature for one month. The effect of temperature and time on the physical 
characteristics of the tablet was evaluated for assessing the stability of the prepared formulations. The 
stability studies were carried out when the room temperature was 200 to 250 C. the different parameter 
that were studied are % drug content,  and in vitro dissolution study. 
 
IN-VITRO STUDY: 
  DISSOLUTION MEDIUM: 0.1 N HCL,900ml, Apparatus type –Basket Type , 
The formulations were subjected to in vitrodissolution study using USP dissolution apparatus. The 
percentage of drug release was calculated for different formulation at different time intervals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL 
MANUFACTURING PROCESS 
FORMULATION OF SUSTAINED RELEASE METOCLOPRAMIDE 
HYDROCHLORIDE MATRIX TABLETS: 
Formulation of sustained release Metoclopramide hydrochloride matrix tablets was done by in two 
steps.  
First step:-Components used for formulation of tablets were mixed properly by using turbula mixer for 
15 minutes. 
Second step: -In second step the above mixture was compressed by using tablet punch machine of 
10mm flat punches   
The tablets were prepared by using different concentration of the polymer and their suitable 
combinations. 
Table -10:Details of design, findings, and summary of key developmental batches 
Ingredients F1 F2 F3 F4 F5 F6 F7 
Metoclopramide 
HCl 
30 30 30 30 30 30 30 
HPMC 90 90 30 90 70 70 70 
Sodium CMC  50 30 90 30 30 50 30 
Mannitol - - - 20 20 20 40 
Microcrystalline 
Cellulose 
30 50 50 30 50 30 30 
Mg Stearate 2 2 2 2 2 2 2 
• All quantity in mg /tablet 
• Compression weight of tablet -202 mg /tab 
Prototype formulation by direct compression method- 
 
The direct compression of tablet performed into three steps   
• Dry Mixing- 
MCC, Mannitol pass through Sieve no 30 and Sodium CMCand HPMC pass through sieve 
no 40 and mix. 
• Lubrication- 
Metoclopramide Hcl, magnesium stearate was bag blended. Blend pass through 40 screens 
and then above dried granules were mixed with the blend in suitable blender. 
• Compression- 
Lubricated granules compressed into tablet by using single rotatory tablet punching 
machine,16 stations. With D tooling 10mm round shape punch set. 
  
RESULT AND DISCUSSION 
 
Tablets with sustained drug delivery were prepared and evaluated with aim to obtain tablet to 
deliver the drug at a controlled and predetermined rate, thus maintaining a therapeutically 
effective concentration of the drug in the systemic circulation for a long period of time. 
Prior to the formulation, preformulation study was carried out on drug and excipients, in the 
present work,formulation part divided in to two steps. In first step, all ingredients with MCP 
Hcl were mixed. 
 In second step the tablets were prepared by using different polymers and its different combination ratio 
were selected for formulation. The detailed composition is shown in table no10 the tablets were 
evaluated for various parameters such as thickness, hardness, friability, weight variation, drug content 
and in-vitro study. 
PREFORMULATION STUDY: 
To ensure the compatibility of drug with excipients the IR spectra for pure drug and prepared powder 
blend was obtained and analyzed for principle peaks.  
The peaks obtained in powder blends of formulations were almost identical to those obtained for pure 
drug reveling that there was no interaction between drug and polymers used in formulations. 
Standard curve of Metoclopramide Hcl: 
Table shows the absorbance readings of Metoclopramide Hclbetween 10-100mcg/ml in 0.1N Hcl. 
 
 
Evaluation of Blend: 
Angle of repose: 
The angles of repose of all formulated batches obtained are shown in table no 12. This implies fair free 
flowing nature of powder blends. These values were found to be satisfactory to give good flow of 
powder blends. 
Hausner ratio:  
The values of Hausner ratio obtained are shown in table no 12. indicating that the powder blends had  
good flow ability and compressibility. 
Bulk Density And Tapped Density: 
The values of bulk density and tapped density obtained are shown in tableno 12. indicating that the 
powder blends had good compressibility. 
Evaluation of tablet 
I) Tablet Dimensions:  
Tablet dimension include thickness and diameter of tablet. Five tablet of each formulation were 
evaluated shown in table no 12. 
II) Hardness:  
Five tablet of each formulation were evaluated and mean hardness values are shown in table.no 12. The 
values reveals that the tablets are having good mechanical strength. 
III)Friability: 
Friability values of each formulation are recorded in tableno 12. . these values are within acceptable 
limit , implies good compactness and strength of each formulation. This also indicates that direct 
compression method is acceptable for technique for formulating rapidly disintegrating sublingual tablet.  
IV)  Weight Variation: 
Twenty tablets of each formulation were evaluated .the mean values of each formulation are recorded in 
tableno 12. The values obtained indicate that all the tablet of different formulations falls within the 
U.S.P. specification. 
The weight variation of all tablets was satisfactory due to good flow  ability of powder blends .desired 
packaging characteristic and uniform dies fill of the formulations. This is supported by the acceptable 
flow properties of powder blend obtained. 
V) Content uniformity of active ingredient: 
The content uniformity was calculated on all the formulation of rapidly disintegrating sublingual 
tablets. The study was carried in triplicate. Tableno 12.shows the results of the drug content uniformity 
in each formulation with S.D.values.  
These values are found satisfactory, which ensures dosage uniformity and meets with requirements of 
USP. 
 
 
 
 
 
 
 
viii) In Vitro Drug Result : 
Table - 11.Standardcalibration values of Metoclopramide Hcl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. no. 
 
CONC 
(mcg/ml) 
ABS 
(nm) 
1 10 0.0733 
2 20 0.1432 
3 30 0.2131 
4 40 0.2782 
5 50 0.3471 
6 60 0.4190 
7 70 0.4867 
8 80 0.5525 
9 90 0.6225 
10 100 0.6950 
Standa
Standar
mcg/ml
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 Fig  8 I.R Spectrum of Metoclopramide Hcl 
 
 
 
 
Fig  9 I.R Spectrum of Metoclopramide Hcl + Excipients 
 
Table .12 Characteristics of powder 
 
Parameter’s F1 F2 F3 F4 F5 F6 F7 
Angle of repose, 
Degrees 
24.21 23.35 21.64 23.85 22.85 21.94 22.88 
Bulk density,g/cm
3
 0.62 0.66 0.42 0.53 0.52 0.56 0.52 
Tapped 
Density,g/cm
3
 
0.71 0.72 0.55 0.62 0.62 0.66 0.63 
% compressibility 14.51 10.65 23.63 14.51 16.12 15.15 17.46 
Hausner ratio 1.14 1.2 1.30 1.17 1.19 1.17 1.21 
Hardness, Kg/cm
2
 5.8 6.1 6.4 6.2 5.7 5.9 6.6 
Thickness , mm 3.17 3.30 3.25 3.40 3.15 3.16 3.20 
% Friability 0.28 0.24 0.12 0.36 0.35 0.18 0.25 
Weight variations 2.4 2.5 2.4 2.6 2.6 2.6 2.3 
% Metoclopramide 
Hcl 96.89 96.42 96.82 100.10 98.77 98.22 98.99 
 
 
 
 
 
 
 
Table  13 -Dissolution profile of all batches 
 
Time(hrs) 
Percent cumulative drug released (Mean ± S.D) 
Formulation code 
F1 F2 F3 F4* F5 F6 F7 
1 
23.31 
± 0.73  
28.34 
±0.96  
25.15 
±1.24  
14.14            
±0.80  
31.32     
±1.28  
42.71            
±0.51  
31.45 
±1.21  
2 
31.25 
±0.46  
34.12    
±1.12  
32.45     
±0.42  
23.15 
±1.06  
41.98            
±1.56  
48.57            
±1.25  
38.41 
±0.76  
4 
42.53 
±0.29  
46.91   
±0.22  
41.17       
±0.80  
42.57  
±1.49  
45.63            
±0.78  
52.71            
±0.46  
47.69 
±1.27  
6 
56.17 
±0.95  
51.19     
±0.49  
55.91       
±1.57  
60.17 
±0.77  
54.13            
±0.39  
58.65            
±2.51  
62.79 
±0.98  
8 
72.37 
±1.31  
61.16 
±1.18  
59.70       
±1.49  
79.37 
±0.93  
60.28            
±2.65  
64.31            
±1.22  
71.24 
±1.37  
10  89.37 ±0.65 
67.34 
±0.80  
63.54      
±0.47  
92.37 
±1.25  
69.47            
±0.85  
71.23            
±0.58  
78.23 
±0.69  
 
 
Conclusion : 
From these data it is concluded that Mannitol and Hydroxy methyl propyl cellulose  improve the 
release of the   drug in F-4 Formulation as compared  to F-1,   F-2,F-3 ,F-5,F-6 and F-7 . 
 
Comparative graph of the formulations (F-1 to F-7) of 
MetoclopramideHydrochloride  
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Fig  10Dissolution profile of metoclopramide HCL 
 
 
 
 
 
 
Table . 14Kinetic modeling of MCP release from different formulations (F-1 to F7) 
 
 
Formula no. 
Zero order model 
R 
Higuchi diffusion model 
R 
F1 0.942 0.996 
F2 0.940 0.994 
F3 0.961 0.992 
F4 0.994 0.999 
F5 0.978 0.989 
F6 0.968 0.990 
F7 0.953 0.993 
 
 
r = correlation coefficient 
 
 
 
 
 
 
  
Fig  11KINETIC TREATMENT DISSOLUTION PROFILE OF F4 BATCH 
(ZEROORDER) 
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 Fig .12  KINETIC TREATMENT DISSOLUTION PROFILE OF F4 BATCH 
(HIGUCHI MODEL) 
Table .15Stability Parameters of F4 batch stored at room temperature. 
 
 
Parameters Initial After 15 days After one month 
 
Drug content (%) 
 
100.10 
 
99.15 
 
99.00 
% drug release (10hrs) 92.37 92.12 91.90 
 
 
Table .16 Stability Parameters of F4 Batch stored at 400C for 75% RH 
 
Parameters Initial After15 days After one month 
Drug Content(%) 100.10 98.90 98.12 
% drug release (10hrs) 92.37  91.12 90.90 
 
Conclusion: 
 
Tablets kept for stability studies were examined. The color of  the  formulation,  i.e.F-4 was similar before 
and after stability studies. Shell texture of the formulation packed in PVC/PVDC (clear) Aluminum 
Blister pack had no change at 40°C /75%RH (±20 C/±5RH) after three months. This indicated that the 
tablets had no effect of moisture from the environment in PVC/PVDC (clear) Aluminum Blister pack. 
SUMMARY AND CONCLUSION 
  
In present work attempts have been made to formulate sustaintedrelase matrix tablet of 
metoclopramide ,by using hydrophilic polymer ,which is preferable used as anti-emetic .  
In present study attempts were made to formulate 202mg sustaindedrelase once daily formulation 
which can provide effective drug relase for 10 hrs. 
Sustained relase matrix tablet of metoclopramide were prepared by direct compression method 
.in vitro study showed formulation F-4 was well suited to be sustained release formulation. 
Matrix tablet were prepared using polymer with HPMC by direct comprssion technique. 
Metoclopramide meets all the characteristic to formulate in the form of sustained relase drug 
delivery system. 
Under the pre formulation study the organoleptic properties were complied with USP 
specification .physical properties such as bulk density and tapped density were more in case of 
granules ready for direct compression. 
The compatibility evaluation werepreformed by FT-IR spectroscopy analysis. A study implies 
that the drug and polymers are compatabile with each other. There were no interaction found 
between polymers and drug. 
The optimized formulation F-4 was evaluated on the basis of pharmacopoeial specification shape 
of the tablet were round convex disc. The physical parameter like length, width 
,thickness,hardness,frability and weight variation is carried out. 
Assay was carried out for optimized formulation and the result were found to be 98.19 % by UV. 
 
Stability study were carried out by kepping the tablet at room temp (25c &60%RH ) and at 
accelerated temp (40c and 75 %) in stability chamber for 30 days. The result of stability studies 
conducted on F-4 reveled no change in physical appearance,drug contain and in vitro dissolution 
profile where spectrum obtained no incompatibility ,hence F-4formulation was found to be stable 
at tested tempreture. 
Final selected formulation were found to be zero order drug relase ,governed by diffusion of 
through swollen matrix and erosion of the matrix ,showing anomalous diffusion of non fickian 
transport . 
From the result obtained ,it can be concluded that formulation F-4 has achieved the objective of 
sustained drug relase ,patient convenience and cost effectiveness as asingle daily dose of the 
drug . 
Overall it was concluded that for the development of controlled release dosage form for poorly 
soluble drug ,polymer blends of different grade of HPMC and presence of disintegrants ,which 
impart the hydrophilic environment and wettability to molecule of drug leads to more uniform 
drug release,respectively . 
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